Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer. Article uri icon

Overview

abstract

  • [This corrects the article DOI: 10.1371/journal.pone.0054014.].

authors

  • Shah, Manish A
  • Wainberg, Zev A
  • Catenacci, Daniel V T
  • Hochster, Howard S
  • Ford, James
  • Kunz, Pamela
  • Lee, Fa-Chyi
  • Kallender, Howard
  • Cecchi, Fabiola
  • Rabe, Daniel C
  • Keer, Harold
  • Martin, Anne-Marie
  • Liu, Yuan
  • Gagnon, Robert
  • Bonate, Peter
  • Liu, Li
  • Gilmer, Tona
  • Bottaro, Donald P

publication date

  • October 10, 2022

Identity

PubMed Central ID

  • PMC9550092

Scopus Document Identifier

  • 85139572536

Digital Object Identifier (DOI)

  • 10.1371/journal.pone.0054014

PubMed ID

  • 36215283

Additional Document Info

volume

  • 17

issue

  • 10